BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 22315367)

  • 1. Aberrant vimentin methylation is characteristic of upper gastrointestinal pathologies.
    Moinova H; Leidner RS; Ravi L; Lutterbaugh J; Barnholtz-Sloan JS; Chen Y; Chak A; Markowitz SD; Willis JE
    Cancer Epidemiol Biomarkers Prev; 2012 Apr; 21(4):594-600. PubMed ID: 22315367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypermethylation of the AKAP12 promoter is a biomarker of Barrett's-associated esophageal neoplastic progression.
    Jin Z; Hamilton JP; Yang J; Mori Y; Olaru A; Sato F; Ito T; Kan T; Cheng Y; Paun B; David S; Beer DG; Agarwal R; Abraham JM; Meltzer SJ
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):111-7. PubMed ID: 18199717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant methylation of secreted frizzled-related protein genes in esophageal adenocarcinoma and Barrett's esophagus.
    Zou H; Molina JR; Harrington JJ; Osborn NK; Klatt KK; Romero Y; Burgart LJ; Ahlquist DA
    Int J Cancer; 2005 Sep; 116(4):584-91. PubMed ID: 15825175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reprimo methylation is a potential biomarker of Barrett's-Associated esophageal neoplastic progression.
    Hamilton JP; Sato F; Jin Z; Greenwald BD; Ito T; Mori Y; Paun BC; Kan T; Cheng Y; Wang S; Yang J; Abraham JM; Meltzer SJ
    Clin Cancer Res; 2006 Nov; 12(22):6637-42. PubMed ID: 17121882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA methylation profiling in Barrett's esophagus and esophageal adenocarcinoma reveals unique methylation signatures and molecular subclasses.
    Kaz AM; Wong CJ; Luo Y; Virgin JB; Washington MK; Willis JE; Leidner RS; Chak A; Grady WM
    Epigenetics; 2011 Dec; 6(12):1403-12. PubMed ID: 22139570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aberrantly methylated PKP1 in the progression of Barrett's esophagus to esophageal adenocarcinoma.
    Kaz AM; Luo Y; Dzieciatkowski S; Chak A; Willis JE; Upton MP; Leidner RS; Grady WM
    Genes Chromosomes Cancer; 2012 Apr; 51(4):384-93. PubMed ID: 22170739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vimentin in upper gastrointestinal pathologies--letter.
    Lind GE; Ahmed D; Lothe RA
    Cancer Epidemiol Biomarkers Prev; 2012 Oct; 21(10):1889; author reply 1890. PubMed ID: 22929079
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.
    Agarwal A; Polineni R; Hussein Z; Vigoda I; Bhagat TD; Bhattacharyya S; Maitra A; Verma A
    Int J Clin Exp Pathol; 2012; 5(5):382-96. PubMed ID: 22808291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA methylation as an adjunct to histopathology to detect prevalent, inconspicuous dysplasia and early-stage neoplasia in Barrett's esophagus.
    Alvi MA; Liu X; O'Donovan M; Newton R; Wernisch L; Shannon NB; Shariff K; di Pietro M; Bergman JJ; Ragunath K; Fitzgerald RC
    Clin Cancer Res; 2013 Feb; 19(4):878-88. PubMed ID: 23243219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cdx2 expression and its promoter methylation during metaplasia-dysplasia-carcinoma sequence in Barrett's esophagus.
    Makita K; Kitazawa R; Semba S; Fujiishi K; Nakagawa M; Haraguchi R; Kitazawa S
    World J Gastroenterol; 2013 Jan; 19(4):536-41. PubMed ID: 23382633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inactivation of p16, RUNX3, and HPP1 occurs early in Barrett's-associated neoplastic progression and predicts progression risk.
    Schulmann K; Sterian A; Berki A; Yin J; Sato F; Xu Y; Olaru A; Wang S; Mori Y; Deacu E; Hamilton J; Kan T; Krasna MJ; Beer DG; Pepe MS; Abraham JM; Feng Z; Schmiegel W; Greenwald BD; Meltzer SJ
    Oncogene; 2005 Jun; 24(25):4138-48. PubMed ID: 15824739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Tissue Systems Pathology Test Detects Abnormalities Associated with Prevalent High-Grade Dysplasia and Esophageal Cancer in Barrett's Esophagus.
    Critchley-Thorne RJ; Davison JM; Prichard JW; Reese LM; Zhang Y; Repa K; Li J; Diehl DL; Jhala NC; Ginsberg GG; DeMarshall M; Foxwell T; Jobe BA; Zaidi AH; Duits LC; Bergman JJ; Rustgi A; Falk GW
    Cancer Epidemiol Biomarkers Prev; 2017 Feb; 26(2):240-248. PubMed ID: 27729357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identifying DNA methylation biomarkers for non-endoscopic detection of Barrett's esophagus.
    Moinova HR; LaFramboise T; Lutterbaugh JD; Chandar AK; Dumot J; Faulx A; Brock W; De la Cruz Cabrera O; Guda K; Barnholtz-Sloan JS; Iyer PG; Canto MI; Wang JS; Shaheen NJ; Thota PN; Willis JE; Chak A; Markowitz SD
    Sci Transl Med; 2018 Jan; 10(424):. PubMed ID: 29343623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data.
    Jammula S; Katz-Summercorn AC; Li X; Linossi C; Smyth E; Killcoyne S; Biasci D; Subash VV; Abbas S; Blasko A; Devonshire G; Grantham A; Wronowski F; O'Donovan M; Grehan N; Eldridge MD; Tavaré S; ; Fitzgerald RC
    Gastroenterology; 2020 May; 158(6):1682-1697.e1. PubMed ID: 32032585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alterations to the Esophageal Microbiome Associated with Progression from Barrett's Esophagus to Esophageal Adenocarcinoma.
    Snider EJ; Compres G; Freedberg DE; Khiabanian H; Nobel YR; Stump S; Uhlemann AC; Lightdale CJ; Abrams JA
    Cancer Epidemiol Biomarkers Prev; 2019 Oct; 28(10):1687-1693. PubMed ID: 31466948
    [TBL] [Abstract][Full Text] [Related]  

  • 16. INK4a-ARF alterations in Barrett's epithelium, intraepithelial neoplasia and Barrett's adenocarcinoma.
    Vieth M; Schneider-Stock R; Röhrich K; May A; Ell C; Markwarth A; Roessner A; Stolte M; Tannapfel A
    Virchows Arch; 2004 Aug; 445(2):135-41. PubMed ID: 15185075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a key role of widespread epigenetic drift in Barrett's esophagus and esophageal adenocarcinoma.
    Luebeck EG; Curtius K; Hazelton WD; Maden S; Yu M; Thota PN; Patil DT; Chak A; Willis JE; Grady WM
    Clin Epigenetics; 2017; 9():113. PubMed ID: 29046735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The molecular genetic alterations in mucosa of intestines as markers of oncologic progression and estimate of effectiveness of anti-reflux operations in patients with Barrett's esophagus].
    Osminin SV; Vetshev FP; Rudenko VV; Zaletaev DV; Khorobrykh TV; Nemtsova MV
    Klin Lab Diagn; 2016 Oct; 61(10):681-5. PubMed ID: 30615323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Global DNA methylation patterns in Barrett's esophagus, dysplastic Barrett's, and esophageal adenocarcinoma are associated with BMI, gender, and tobacco use.
    Kaz AM; Wong CJ; Varadan V; Willis JE; Chak A; Grady WM
    Clin Epigenetics; 2016; 8():111. PubMed ID: 27795744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation Biomarker Panel Performance in EsophaCap Cytology Samples for Diagnosing Barrett's Esophagus: A Prospective Validation Study.
    Wang Z; Kambhampati S; Cheng Y; Ma K; Simsek C; Tieu AH; Abraham JM; Liu X; Prasath V; Duncan M; Stark A; Trick A; Tsai HL; Wang H; He Y; Khashab MA; Ngamruengphong S; Shin EJ; Wang TH; Meltzer SJ
    Clin Cancer Res; 2019 Apr; 25(7):2127-2135. PubMed ID: 30670490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.